

R&D PORTFOLIO June 2026 – 14 treatments delivered

	DISCOVERY			TRANSLATION			DEVELOPMENT		IMPLEMENTATION
	Screening	Hit-to-lead	Lead optimization	Pre-clinical	Phase I	Phase IIa/ Proof-of-concept	Phase IIb/III	Registration	Treatment access
SLEEPING SICKNESS									Acoziborole* Fexinidazole for <i>T.b. rhodesiense</i> * Fexinidazole for <i>T.b. gambiense</i> * Nifurtimox-eflornithine combination therapy (NECT)*
LEISHMANIASIS				Translational platform	DNDI-6148 DNDI-6899 (GSK899 DDD853651) DNDI-6174 CpG-D35 (DNDI-2319) for CL	LXE408 for CL LXE408 for VL	Miltefosine + paromomycin for VL (Africa) Miltefosine + paromomycin or LAmB for PKDL (Eastern Africa) LAmB +/- miltefosine for PKDL (South Asia) Miltefosine + thermotherapy for CL		SSG + PM (East Africa)* New VL treatments (South Asia)* New treatments for VL/HIV* New VL treatments (Latin America)*
CHAGAS DISEASE	Screening	Hit-to-lead	UW series	Biomarkers Translational platform	Oxaborole		New benznidazole regimens		Benznidazole paediatric dosage forms*
PARASITIC WORMS incl. filariasis & schistosomiasis				AR102 (schistosomiasis) Translational platform (schistosomiasis)		Emodepside (filarial) Oxfendazole (filarial)	Paediatric ivermectin (filarial) Praziquantel/anti-inflammatory (FGS)		
MYCETOMA				Translational platform				Fosravuconazole	New treatments for mycetoma
DENGUE				Pre-clinical profiling			SII dengue mAb Montelukast + rupatidine		
HIV						SR 5FC (cryptococcal meningitis)			Super-booster for children with HIV/TB* 4-in-1 (ABC/3TC/LPV/r)* and other DAAs AHD access (incl. 5FC, LAmB for cryptococcal meningitis) 2-in-1 LPV/r pellets
HEPATITIS C									Ravidasvir* and other DAAs
PANDEMIC PREPAREDNESS		Flavivirus hit-to-lead	AVIDD ASAP Flavivirus protease TMEM16 Series	ASAP-0017445 (Moonshot ASAP)					
MALARIA									Fixed-dose combination ASMQ* Fixed-dose combination ASAQ*

⚙ New chemical entity (NCE) or NCE-enabling project * Treatments delivered by DNDi with partners ▶ Treatments not delivered by DNDi, but DNDi working on access >> Implementation transferred to the Medicines for Malaria Venture in 2015

